Literature DB >> 16868809

Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension.

Ying-Wen Wang1, Han-Chieh Lin, Ying-Ying Yang, Ming-Chih Hou, Shou-Dong Lee.   

Abstract

Portopulmonary hypertension is a recognized but uncommon complication of cirrhosis. Liver transplantation may be contraindicated in patients with severe portopulmonary hypertension. In order to decrease the pulmonary arterial pressure, intravenous administration of epoprostenol has been shown to provide substantial beneficial results in these patients. Additionally, a recent case report demonstrated that long-term oral administration of sildenafil decreased pulmonary arterial pressure, but its effects on splanchnic hemodynamics were not measured. We report on a patient with cirrhosis and portopulmonary hypertension and the changes in the hemodynamic status after an oral administration of sildenafil. This case report clearly delineates that sildenafil decreases pulmonary arterial pressure but may exacerbate portal hypertension and hyperdynamic circulation in patients with cirrhosis and portopulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868809     DOI: 10.1007/s00535-006-1809-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  31 in total

Review 1.  Primary pulmonary hypertension.

Authors:  L J Rubin
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

2.  Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis.

Authors:  H C Lin; Y T Tsai; F Y Lee; S D Lee; H C Hsia; W J Lin; K J Lo
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

Review 3.  Recent insights into the pathogenesis and therapeutics of pulmonary hypertension.

Authors:  Julian W Strange; John Wharton; Peter G Phillips; Martin R Wilkins
Journal:  Clin Sci (Lond)       Date:  2002-03       Impact factor: 6.124

4.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.

Authors:  R M Wallis; J D Corbin; S H Francis; P Ellis
Journal:  Am J Cardiol       Date:  1999-03-04       Impact factor: 2.778

5.  Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.

Authors:  M J Krowka; R P Frantz; M D McGoon; C Severson; D J Plevak; R H Wiesner
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

6.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

Review 7.  Primary pulmonary hypertension.

Authors:  James R Runo; James E Loyd
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

Review 8.  Diagnosis and differential assessment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Adam Torbicki; Olivier Sitbon; Michael J Krowka; Horst Olschewski; Sean Gaine
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

9.  Sildenafil (viagra) is a risk factor for acute variceal bleeding.

Authors:  Charalabos Tzathas; Ageliki Christidou; Spiros D Ladas
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864

10.  Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure.

Authors:  Marco Guazzi; Gabriele Tumminello; Fabio Di Marco; Maurizio D Guazzi
Journal:  Clin Pharmacol Ther       Date:  2004-10       Impact factor: 6.875

View more
  10 in total

1.  Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.

Authors:  Christian M Kähler; Ivo Graziadei; Helene Vogelsinger; Susanna Desole; Katharina Cima; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2011-03-31       Impact factor: 1.704

2.  Circulating endotoxin and interleukin-6 levels are associated with Doppler-evaluated pulmonary vascular resistance in cirrhotic patients.

Authors:  Georgios N Kalambokis; Athanasia Mouzaki; Maria Rodi; Konstantinos Pappas; Panagiotis Korantzopoulos; Epameinondas V Tsianos
Journal:  Hepatol Int       Date:  2012-02-02       Impact factor: 6.047

Review 3.  Pulmonary complications of hepatic diseases.

Authors:  Salim R Surani; Yamely Mendez; Humayun Anjum; Joseph Varon
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 4.  Hepatic encephalopathy: effects of liver failure on brain function.

Authors:  Vicente Felipo
Journal:  Nat Rev Neurosci       Date:  2013-10-23       Impact factor: 34.870

5.  Sildenafil reduces neuroinflammation and restores spatial learning in rats with hepatic encephalopathy: underlying mechanisms.

Authors:  Vicente Hernandez-Rabaza; Ana Agusti; Andrea Cabrera-Pastor; Santos Fustero; Oscar Delgado; Lucas Taoro-Gonzalez; Carmina Montoliu; Marta Llansola; Vicente Felipo
Journal:  J Neuroinflammation       Date:  2015-10-29       Impact factor: 8.322

6.  Baicalin prevents pulmonary arterial remodeling in vivo via the AKT/ERK/NF-κB signaling pathways.

Authors:  Guosen Yan; Jinxia Wang; Tao Yi; Junfen Cheng; Haixu Guo; Yuan He; Xiaorong Shui; Zeyong Wu; Shian Huang; Wei Lei
Journal:  Pulm Circ       Date:  2019-11-05       Impact factor: 2.886

7.  Sildenafil does not have a significant effect on the portal vein velocity, cross-sectional area, and congestion index in the dog.

Authors:  Christopher R Tollefson; Marc A Seitz; Claudio C Natalini; Alison M Lee
Journal:  Front Vet Sci       Date:  2022-07-19

8.  Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.

Authors:  Leonie Halverscheid; Peter Deibert; René Schmidt; Hubert E Blum; Torsten Dunkern; Benedikt H J Pannen; Wolfgang Kreisel
Journal:  BMC Gastroenterol       Date:  2009-09-18       Impact factor: 3.067

9.  Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report.

Authors:  Hinrich C Bremer; Wolfgang Kreisel; Kai Roecker; Michael Dreher; Daniel Koenig; Anna Katharina Kurz-Schmieg; Hubert E Blum; Martin Roessle; Peter Deibert
Journal:  J Med Case Rep       Date:  2007-07-10

10.  Numerical investigation of the haemodynamics in the human fetal umbilical vein/ductus venosus based on the experimental data.

Authors:  Taraneh Rezaee; Kamran Hassani
Journal:  Biosci Rep       Date:  2016-09-29       Impact factor: 3.840

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.